Results 41 to 50 of about 21,316 (178)

A case of antithyroid drug‐induced agranulocytosis from a second antithyroid drugs (ATD) administration in a relapsed Graves' disease patient who was tolerant to the first ATD treatment

Clinical Case Reports, 2018
Key Clinical Message Agranulocytosis is a rare side effect of antithyroid drugs (ATD) that usually develops within the first 3‐6 months after starting treatment.
Hyunsam Kim, Jeongmin Lee, Jeonghoon Ha
doaj   +1 more source

Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose

Drugs in R&D, 2023
Background and objective Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole.
Raphael Allgaier, Arne Kandulski, Karsten Gülow, Lars Maier, Martina Müller, Hauke Christian Tews   +5 more
doaj   +1 more source

Cystitis in guinea pigs (Cavia porcellus): Clinical findings and treatment outcomes

Veterinary Record, EarlyView.
Abstract Background This retrospective study examined the incidence, diagnostic methods, bacterial isolates, treatments and outcomes associated with cystitis in guinea pigs presented at a single clinic between 2009 and 2022. Methods The clinic's medical records database was reviewed using easyvet software to identify cases eligible for inclusion in the
Anika Mische, Kerstin Müller
wiley   +1 more source

Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis

BMC Neurology, 2021
Background Lacosamide (LCM) is the antiepileptic drug approved by the U.S. Food and Drug Administration in 2008 that facilitates slow activation of the voltage-gated sodium channels.
Makoto Shibata, Reona Hoshino, Chisato Shimizu, Masayuki Sato, Natsumi Furuta, Yoshio Ikeda   +5 more
doaj   +1 more source

Predicting clozapine-induced adverse drug reaction biomarkers using machine learning

Scientific Reports
Clozapine is an atypical antipsychotic used for patients with treatment-resistant schizophrenia. This drug has serious adverse drug reactions (ADRs), including the risk of severe neutropenia (agranulocytosis).
John-Paul Cooper, Pierre Chue, Arno G. Siraki, Lusine Tonoyan   +3 more
doaj   +1 more source

Unusual Synchronous Methimazole-Induced Agranulocytosis and Severe Hepatotoxicity in Patient with Hyperthyroidism: A Case Report and Review of the Literature

International Journal of Endocrinology, 2015
Context. To report a patient with hyperthyroidism who developed concurrent occurrence of agranulocytosis and severe hepatotoxicity after taking methimazole (MMI). Case.
Jun Yang, Jun Zhang, Qin Xu, Guo-ping Sheng, Wan-wen Weng, Meng-jie Dong   +5 more
doaj   +1 more source

Considerations of HLA, Renal Failure, Valproic Acid Use, and Current Treatment Guidelines in Clozapine-Induced Agranulocytosis

Case Reports in Psychiatry, 2021
Clozapine, the choice atypical antipsychotic for refractory schizophrenia, schizoaffective disorder, and bipolar disorder, has been shown to reduce positive and negative symptoms of schizophrenia.
Melissa Sussman, Michael Epifania, Derrick Eng, Yun Jae Cho, Richard Steward   +4 more
doaj   +1 more source

Phenotype‐specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20‐year cohort study

British Journal of Haematology, EarlyView.
Summary Childhood autoimmune neutropenia (AIN) encompasses heterogeneous entities; phenotype‐specific immunological profiles and their relationship to infection outcomes remain incompletely defined. To characterise clinical, immunological and long‐term outcomes across distinct phenotypes of childhood AIN.
Ioanna Saougou, Chrysoula Kosmeri, Nikolaos Chaliasos, Irene Mavroudi, Charalampos Pontikoglou, Alexandros Makis   +5 more
wiley   +1 more source

Neutropenia, agranulocytosis and dipyrone

São Paulo Medical Journal
CONTEXT: Neutropenia and agranulocytosis may be defined as granulocyte counts of less than 1,500/mm³ and 500/mm³, respectively. Agranulocytosis is a rare and serious disease often caused by drugs. Its mortality rate is around 10%.
Nelson Hamerschlak, Alexandre Biasi Cavalcanti   +1 more
doaj   +1 more source

Safety and Efficacy of Iron Chelators in Patients With Chronic Kidney Disease: A Systematic Review and Meta‐Analysis

Hemodialysis International, EarlyView.
ABSTRACT Background Iron overload in chronic kidney disease contributes to oxidative injury. The role of iron chelators, standard in transfusion‐related overload, remains unclear in chronic kidney disease. Aim To evaluate the efficacy and safety of iron chelators in adults with chronic kidney disease.
Humam Emad Rajha, Richard Shamoon, Ameer Almeshagbeh, Samah Masry, Fadel Alqatati, Baha H. Abuajameia, Abdulqadir J. Nashwan   +6 more
wiley   +1 more source